Search

everythinglearnresearchcommunity

for

Search:↓

A six month update of the users' experience with Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841.

Adding Pyri to a hair loss treatment stack. The user is inquiring about its effectiveness and side effects.

Pyrilutamide is being discussed as a potential hair loss treatment, but opinions are mixed, with some users skeptical about its effectiveness and the company's credibility. Some users report combining pyrilutamide with other treatments like dutasteride and microneedling, noting improvements, while others remain doubtful.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The conversation is about skepticism towards the hair loss treatments RU58841 and Pyrilutamide, with users discussing the lack of human testing for RU58841 and the ongoing trials for Pyrilutamide. Some users believe RU58841 has more anecdotal success, while others highlight Pyrilutamide's current research progress.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

Azelaic acid is considered a strong DHT inhibitor with no reported sexual side effects, making it a potential alternative for those who cannot use finasteride. It can be used with minoxidil, but may cause skin irritation.

The user switched from Pyrilutamide to RU58841, changed their Minoxidil solution, and continued using low-dose Finasteride, derma rolling, and specific shampoo. They asked others about their plans after Pyrilutamide's disappointing results.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Microneedling before a hair transplant may harden the scalp and affect blood circulation, potentially impacting graft growth. Some users report successful transplants after microneedling, while others advise caution and consulting with a surgeon.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

The conversation is about a user's progress in treating diffuse hair thinning using a topical regimen including finasteride, minoxidil, ketoconazole, microneedling, saw palmetto, collagen, and vitamins, along with lifestyle changes. The user plans to switch from topical to oral finasteride for potentially better results.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

The conversation discusses the link between seborrheic dermatitis, acne, and male pattern baldness, suggesting that DHT may cause both skin conditions and hair loss. Treatments mentioned include RU58841, finasteride, dutasteride, minoxidil, Nizoral shampoo, and other topical anti-androgens.

A user discusses using a 1.5mm dermaroller daily in the shower for hair loss, noting redness but no bleeding, and applying coconut oil afterward. They are concerned about a receding hairline and slight hair loss near the temple.

A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.

Using Pyrilutamide or RU as monotherapy for hair loss? Share experiences.

The acne medication Winlevi, which contains Clascoterone, is available in the U.S. and may slow down hair loss until a higher concentration treatment, Breezula, is released.

Adding creatine while using finasteride and minoxidil caused skin irritation and hair thinning. Creatine may affect DHT levels, leading to these issues.

A user discusses using dermastamping for hair loss and questions the timing of applying a mixture of peppermint oil, spearmint oil, rosemary oil, and castor oil due to their anti-inflammatory effects. They wonder if waiting 10 hours after stamping would be more effective.

Hair loss treatments discussed include Minoxidil, Finasteride, RU58841, Alfatradiol, and Eucapil. Topical treatments must penetrate skin and may go systemic, with effectiveness varying.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

Avoid burning or scarring the scalp for hair growth; instead, use treatments like finasteride, minoxidil, or consider a hair transplant. Microneedling should be done carefully, and extreme methods can cause harm.

The user experienced initial hair density improvement with finasteride, but later felt scalp pain and a plateau in results. They added alfatradiol for scalp inflammation and divi scalp serum to their routine, and are curious if others have similar experiences.

A user experienced increased pimples and cysts after two years on dutasteride, possibly due to hormonal changes. Suggestions included seeing an endocrinologist, using supplements like boron and DIM, adjusting diet, and reducing body fat to manage side effects.

The conversation discusses adding either RU58841 or pyrilutamide to a hair loss treatment regimen that already includes oral dutasteride and oral minoxidil. RU58841 is considered the stronger anti-androgen but may have more side effects.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.